BUKWANG PHARMACEUTICAL IND CO.,LTD
Founded 1960, KOSPI-listed 1988, Bukwang Pharmaceutical makes Dexid, Levovir, and Latuda, and licensed MLR-1023 to Melior and Biodexa.
As of 2026-10-08, BUKWANG PHARMACEUTICAL IND CO.,LTD has 224 Korean MFDS drug approvals, 1 PubMed-indexed paper on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureBukwang Pharmaceutical was founded on October 17, 1960 and listed on the KOSPI on August 5, 1988. It manufactures and sells pharmaceuticals and quasi-drugs including Dexid, Levovir, Latuda, Legalon, Thioctacid, and Synthyroid, and runs R&D programs such as CP-012. Consolidated revenue reached KRW 200.7 billion (up ~25% year-on-year) and operating profit rose 784% to KRW 14.2 billion, while it licensed out MLR-1023 to Melior Pharmaceuticals and Biodexa Pharmaceuticals.
Products & technology
- Levovir (Clevudine)Chronic hepatitis B treatment
- Dexid (R-thioctic acid tromethamine)Diabetic neuropathy treatment
- LatudaSchizophrenia, bipolar depression treatment
Regulatory approvals
data.go.kr2 Orphan Drug designations · 2016–2017 / 224 Korean MFDS drug approvals · 1963–2026
- OrphanJM-0102017-01-04Orphan Drug designation · in development20160183139
- Orphan아파티닙메실레이트정제2016-02-03Orphan Drug designation · in development20150193669
- MFDS drugErozet Tab. 1/10mg2026-04-24Drug · Prescription · Approval202601207
- MFDS drugLodivan Tab. 2.5/80mg (Amlodipine Besylate, Valsartan)2026-02-25Drug · Prescription · Approval202600576
- MFDS drugBukwang Brifil Tab. 25 mg2025-09-19Drug · Prescription · Approval202502485
- MFDS drugBukwang Brifil Tab. 10 mg2025-09-19Drug · Prescription · Approval202502486
- MFDS drugBukwang Brifil Tab. 50 mg2025-09-19Drug · Prescription · Approval202502487
- MFDS drugBukwang Brifil Tab. 100 mg2025-09-19Drug · Prescription · Approval202502488
- MFDS drugAriplus tablet 10/20mg2024-12-27Drug · Prescription · Approval202403090
- MFDS drugLATUDA 120mg tablets2023-11-23Drug · Prescription · Approval202303204
- MFDS drugLATUDA 80mg tablets2023-11-23Drug · Prescription · Approval202303205
- MFDS drugLATUDA 60mg tablets2023-11-23Drug · Prescription · Approval202303206
Show 68 more
- MFDS drugLATUDA 20mg tablets2023-11-23Drug · Prescription · Approval202303207
- MFDS drugLATUDA 40mg tablets2023-11-23Drug · Prescription · Approval202303208
- MFDS drugMegabraynon Capsule2023-11-16Drug · OTC · Notification202303156
- MFDS drugTacenol Kids Syrup(Acetaminophen)2023-09-26Drug · OTC · Notification202302828
- MFDS drugBengdelong S Syrup2023-07-24Drug · OTC · Notification202302217
- MFDS drugTacenol Ibu Soft Cap 400 mg(Ibuprofen)2023-05-11Drug · OTC · Notification202301519
- MFDS drugSaponal S GranuleRevoked2023-05-03Drug · OTC · Notification202301442
- MFDS drugTacenol Cold Syrup2023-03-31Drug · OTC · Notification202301092
- MFDS drugTacenolen hanbang Soft Ext.2023-01-16Drug · OTC · Notification202300264
- MFDS drugVita Angel Chewable Tab.2022-12-27Drug · OTC · Notification202204643
- MFDS drugTacenol Cold Cap.2022-12-23Drug · OTC · Notification202204622
- MFDS drugMGMax Plus B Soft Cap.2022-12-09Drug · OTC · Notification202204454
- MFDS drugMGMax Speed Solution2022-12-08Drug · OTC · Notification202204434
- MFDS drugZaledeep Capsule 5mg(zaleplon)2022-06-29Drug · Prescription · Approval202202678
- MFDS drugZaledeep Capsule 10mg(zaleplon)2022-06-29Drug · Prescription · Approval202202679
- MFDS drugBukwang Ascorbic Acid Tab.500mg2022-06-20Drug · OTC · Approval202202571
- MFDS drugTacenol Tab. 160mg2022-04-27Drug · OTC · Notification202201721
- MFDS drugOzanex Cream2021-12-10Drug · Prescription · Approval202107880
- MFDS drugHardcal C Plus Tablet2021-10-07Drug · OTC · Notification202106791
- MFDS drugBudian Tab. 25mg2021-07-23Drug · Prescription · Approval202105536
- MFDS drugBudian Tab. 10mg2021-07-23Drug · Prescription · Approval202105537
- MFDS drugWisogen Tablet2021-03-15Drug · OTC · Notification202102295
- MFDS drugNaevaren Q Sol.2021-03-09Drug · OTC · Notification202102183
- MFDS drugBukwang Methimazole Tablet 2.5mg2021-01-20Drug · Prescription · Approval202100592
- MFDS drugZemple D Injection2020-11-30Drug · Prescription · Approval202008320
- MFDS drugCircaledeep PR Tab. 2mg (Melatonin)2020-09-22Drug · Prescription · Approval202006550
- MFDS drugFamertidine Tab.2020-08-25Drug · OTC · Notification202005998
- MFDS drugBukwang kyungokgo2020-05-22Drug · OTC · Notification202003751
- MFDS drugBukwang Midazolam Injection 15mg/3mL(for export)2020-04-13Drug · Prescription · Approval202002585
- MFDS drugCotrina Cap.2020-04-06Drug · OTC · Notification202002383
- MFDS drugMG Max Plus Soft Cap.Revoked2020-03-02Drug · OTC · Notification202001470
- MFDS drugActiby Tab.2019-12-16Drug · OTC · Notification201908441
- MFDS drugSynthyroid Tablet 0.025mg2019-05-21Drug · Prescription · Approval201903264
- MFDS drugSynthyroid Tablet 0.0375mg2019-05-07Drug · Prescription · Approval201902912
- MFDS drugNavelbine Soft Capsule 20mgRevoked2019-02-15Drug · Prescription · Approval201900960
- MFDS drugNavelbine Soft Capsule 30mgRevoked2019-02-15Drug · Prescription · Approval201900961
- MFDS drugSynthyroid Tablet 0.112mg2019-01-10Drug · Prescription · Approval201900107
- MFDS drugSynthyroid Tablet 0.2mg2018-10-26Drug · Prescription · Approval201804237
- MFDS drugSaponal GranuleRevoked2018-06-11Drug · OTC · Notification201802402
- MFDS drugLegaliver 350 Soft Cap.2018-03-30Drug · OTC · Notification201801423
- MFDS drugDermomedi Q Solution2018-02-27Drug · OTC · Notification201800949
- MFDS drugTacenol 8 hours ER Tablet 325mg2018-01-30Drug · OTC · Approval201800567
- MFDS drugHexamedine Solution 0.12%2017-12-11Drug · OTC · Notification201708285
- MFDS drugLegadex Cap.2017-09-18Drug · Prescription · Approval201707113
- MFDS drugFreead Tablet2017-08-11Drug · Prescription · Approval201706556
- MFDS drugAlaxyl Soft Syrup2017-08-09Drug · OTC · Notification201706514
- MFDS drugCentella Tab.2017-06-19Drug · OTC · Notification201703991
- MFDS drugFerroba Momscare Tab.2016-11-10Drug · OTC · Notification201606593
- MFDS drugTelmistan Tablet 40/5mg2016-09-30Drug · Prescription · Approval201605819
- MFDS drugTelmistan Tablet 80/5mg2016-09-30Drug · Prescription · Approval201605820
- MFDS drugTelmistan Tablet 40/10mgRevoked2016-09-30Drug · Prescription · Approval201605821
- MFDS drugSynthyroid Tablet 0.075mg2016-08-31Drug · Prescription · Approval201605340
- MFDS drugLiptoc Care Sol.2016-08-26Drug · OTC · Notification201605110
- MFDS drugCleatoc Topical Solution 2%2016-07-14Drug · OTC · Notification201604351
- MFDS drugPregastar Capsule 75mg2016-06-21Drug · Prescription · Approval201603681
- MFDS drugPregastar Capsule 150mg2016-06-21Drug · Prescription · Approval201603682
- MFDS drugPregastar Capsule 300mg2016-06-21Drug · Prescription · Approval201603683
- MFDS drugFBex Cataplasma2016-04-26Drug · OTC · Notification201602322
- MFDS drugFBex Hanbang Cataplasma2016-04-26Drug · OTC · Notification201602323
- MFDS drugCleamild Oinment2016-04-22Drug · OTC · Notification201602246
- MFDS drugPhazyme-air free Chewable Tab.2016-01-08Drug · OTC · Approval201600173
- MFDS drugBusomezole Tablet 40mg2015-09-30Drug · Prescription · Approval201506832
- MFDS drugBusomezole Tablet 20mg2015-09-30Drug · Prescription · Approval201506833
- MFDS drugNailstar Nail Lacquer2015-08-24Drug · OTC · Notification201505910
- MFDS drugKids Add Chewable Tab.2015-07-23Drug · OTC · Notification201505023
- MFDS drugExphen Cap.Revoked2015-07-17Drug · OTC · Notification201504904
- MFDS drugTacenol Tab. 500mg2015-07-16Drug · OTC · Notification201504877
- MFDS drugLonasen Tablet 8mg2015-06-29Drug · Prescription · Approval201504175
Showing the 80 most recent of 226 records.
Clinical trials
data.go.kr16 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 7 · Phase 2 4 · Phase 3 2 · Phase 1 2 · Phase 2a 1)
- Phase 3라투다정2026-06-02
19 trial sites
- Bioequivalence부광사피나미드정50밀리그램(가칭)(사피나미드메실산염)2025-09-10
2 trial sites
- Bioequivalence소마지나정500밀리그램(시티콜린나트륨)2024-09-02
2 trial sites
- Phase 2JM-0102022-11-07
10 trial sites
- Phase 2레보비르캡슐30mg(클레부딘)2021-01-07
11 trial sites
- Phase 2레보비르캡슐30mg(클레부딘)2020-04-14
10 trial sites
- Bioequivalence씬지로이드정0.2밀리그램(레보티록신나트륨수화물)2017-11-07
2 trial sites
- Phase 3Lurasidone HCl(SM-13496)2017-08-01
35 trial sites
- Phase 2MLR-1023필름코팅정2017-02-10
21 trial sites
- Bioequivalence리단정(탄산리튬)2017-01-12
2 trial sites
- Bioequivalence부광이소맥지속성캡슐(이소소르비드이질산염지속과립)2016-10-11
2 trial sites
- Phase 1BKP-15022016-05-02
1 trial site
Show 4 more
- Phase 2aMLR-1023필름코팅정2014-09-16
10 trial sites
- Bioequivalence크레틴정 20밀리그램2013-04-16
2 trial sites
- Bioequivalence부광이소맥지속성캅셀(지속성질산이소소르비드펠렛)2012-07-16
- Phase 1BKP-10032012-02-22
1 trial site
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 3 · Not yet recruiting · 2026-09 · NCT07781293
Phase 1 · Completed · 2023-08 · NCT06014853
Phase 2 · Terminated · 2021-04 · NCT04377945
Phase 2 · Completed · 2021-03 · NCT04891302
Phase 2 · Completed · 2020-05 · NCT04347915
Phase 3 · Completed · 2018-04 · NCT03465787
Phase 1 · Completed · 2016-03 · NCT02711969
Phase 2 · Completed · 2015-05 · NCT02439203
Phase 1 · Completed · 2012-04 · NCT01624779
Phase 1 · Completed · 2012-04 · NCT01581242
Show 24 more trials
Phase 4 · Completed · 2011-12 · NCT01507922
Phase 3 · Completed · 2010-11 · NCT01258686
Phase 3 · Completed · 2010-08 · NCT01261143
Phase 4 · Completed · 2010-06 · NCT01263002
Phase 4 · Completed · 2010-03 · NCT01264354
Phase 4 · Terminated · 2009-11 · NCT01264094
Phase 4 · Terminated · 2009-09 · NCT01264133
Phase 1 · Completed · 2009-08 · NCT01258699
Phase 4 · Terminated · 2009-08 · NCT01266005
Completed · 2009-04 · NCT01264107
Phase 4 · Completed · 2008-12 · NCT01264367
Phase 4 · Completed · 2008-02 · NCT00641082
Phase 3 · Completed · 2007-12 · NCT00672867
Phase 4 · Completed · 2007-11 · NCT00558493
Phase 4 · Completed · 2007-06 · NCT00558818
Phase 4 · Completed · 2007-05 · NCT00501124
Phase 3 · Completed · 2006-08 · NCT00362635
Completed · 2005-06 · NCT00362674
Phase 3 · Terminated · 2004-06 · NCT00362505
Phase 2 · Terminated · 2003-07 · NCT00362700
Phase 3 · Terminated · 2003-07 · NCT00313274
Phase 3 · Terminated · 2003-06 · NCT00313287
Phase 2 · Terminated · 2003-06 · NCT00313261
Phase 2 · Terminated · 2002-07 · NCT00305019
R&D and key agreements
Source: DART corporate disclosureMLR-1023 · 대사장애 및 관련 질환(당뇨병) · 제2형 당뇨병 Phase 2a·2b 완료(미국, 한국); 제1형 당뇨병 Phase 2a 진행 중(캐나다) · Bukwang returned its Asia (ex-Japan) in-licensed rights from Melior and out-licensed one of its own patents worldwide; Melior subsequently sub-licensed to Biodexa
CP-012 · Listed as a key product of the pharmaceutical R&D business segment
Key disclosures
KRX KIND via OpenDARTShow 3 more events
Publications
PubMed · affiliation-matched- A new antithrombotic agent, aspalatone, attenuated cardiotoxicity induced by doxorubicin in the mouse; possible involvement of antioxidant mechanism.
Life sciences · 1997-01 · Kim C, Nam SW, Choi DY 외 4
Patents
KIPRIS · applicant-matchedWithdrawn · 2022-05 · Application 1020220060529
Registered · 2020-04 · Application 1020200046764
Withdrawn · 2018-01 · Application 1020180010271
Registered · 2016-10 · Application 1020160143433
Withdrawn · 2016-03 · Application 1020160029733
Rejected · 2014-12 · Application 1020140169522
Rejected · 2010-05 · Application 1020100046543
Rejected · 2010-04 · Application 1020100036875
Rejected · 2009-07 · Application 1020090066287
Rejected · 2007-06 · Application 1020070054962
Show 33 more patents
Registered · 2007-03 · Application 1020070025857
Registered · 2006-12 · Application 1020060124497
Registered · 2006-11 · Application 1020060119180
Expired · 2005-09 · Application 1020050081577
Expired · 2005-06 · Application 1020050056032
Expired · 2003-10 · Application 1020030070122
Expired · 2003-04 · Application 1020030024280
Registered · 2003-01 · Application 1020030003035
Expired · 2002-03 · Application 1020037012772
Expired · 2001-10 · Application 1020010065967
Expired · 2001-08 · Application 1020010053367
Expired · 2001-08 · Application 1020010050606
Expired · 2001-04 · Application 1020010019934
Expired · 2001-04 · Application 1020010018829
Expired · 2001-03 · Application 1020010011235
Expired · 2001-02 · Application 1020010004864
Expired · 2001-02 · Application 1020010004873
Expired · 2001-01 · Application 1020010003233
Expired · 1999-09 · Application 1019990040634
Expired · 1999-09 · Application 1019990040382
Expired · 1998-07 · Application 1019980029927
Expired · 1998-03 · Application 1019980010753
Withdrawn · 1998-01 · Application 1019980002073
Expired · 1995-01 · Application 1019950001085
Expired · 1994-12 · Application 1019940032645
Expired · 1994-04 · Application 1019940007733
Rejected · 1994-03 · Application 2019940006251
Expired · 1993-09 · Application 1019930017428
Rejected · 1991-07 · Application 1019910012910
Expired · 1991-03 · Application 1019910003880
Expired · 1987-01 · Application 1019870000558
Expired · 1978-11 · Application 1019780003595
Expired · 1973-12 · Application 1019730002131
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIOAI-SearchBot64
- PerplexityPerplexityBot3
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for BUKWANG PHARMACEUTICAL IND CO.,LTD and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition